SCHEMBL7215429

SCHEMBL7215429

O=Cc1ccc(-c2cccc(C(F)(F)F)c2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 3/20 0.56
DRD1 P21728 1/20 0.51
MAOB P27338 1/20 0.51
KDM1A O60341 1/20 0.50
TRPM2 O94759 1/20 0.48
ALDH1A1 P00352 1/20 0.48
POLB P06746 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
PGR P06401 1/20 0.48
PTPN1 P18031 2/20 0.46
CA12 O43570 1/20 0.46
CA9 Q16790 1/20 0.46
PTPN5 P54829 1/20 0.45
PARP10 Q53GL7 1/20 0.44
PARP11 Q9NR21 1/20 0.44
ASIC3 Q9UHC3 1/20 0.44
S1PR5 Q9H228 1/20 0.44
BACE1 P56817 1/20 0.44
SLC13A5 Q86YT5 1/20 0.44
TRIM24 O15164 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30679628 1.00 KIF11 (0.56) KIF11DRD1MAOBKDM1ATRPM2
Trifluoroacetic Acid SCHEMBL28927044 0.91 KIF11 (0.52) KIF11DRD1MAOBTRPM2ALDH1A1
SCHEMBL13221440 0.83 KIF11 (0.56) KIF11DRD1ALDH1A1POLBL3MBTL1
SCHEMBL26827704 0.82 MAOB (0.62) KIF11MAOBKDM1APGRPTPN1
SCHEMBL1427373 0.82 TRIM24 (0.56) KIF11DRD1MAOBALDH1A1PTPN1
SCHEMBL27882694 0.82 MAOB (0.51) KIF11MAOBKDM1ATRPM2ALDH1A1
SCHEMBL24106776 0.81 KIF11 (0.67) KIF11MAOBKDM1AALDH1A1PGR
SCHEMBL16068255 0.81 KIF11 (0.67) KIF11MAOBKDM1AALDH1A1PGR
SCHEMBL2268468 0.81 KIF11 (0.56) KIF11DRD1
SCHEMBL26821704 0.81 KIF11 (0.67) KIF11MAOBKDM1AALDH1A1PGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113631548-A Serotonin 5-HT2B inhibiting compounds 硕腾服务有限责任公司 2021-11-09 CN claimed
EP-4570313-A2 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2025-06-18 EP disclosed
CN-117430570-A Rhodamine acetic acid compound, and pharmaceutical composition and application thereof 中国医学科学院药物研究所 2024-01-23 CN disclosed
EP-4219477-A1 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2023-08-02 EP disclosed
CN-113631548-A Serotonin 5-HT2B inhibiting compounds 硕腾服务有限责任公司 2021-11-09 CN disclosed
EP-3694840-B1 PIPERAZINE DERIVATIVES AS MAGL INHIBITORS HOFFMANN LA ROCHE (CH) 2021-08-04 EP disclosed
US-10626095-B2 Cyanotriazole compounds OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2020-04-21 US disclosed
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2016-08-11 US disclosed
US-20100216762-A1 Agonists and Antagonists of the S1P5 Receptor, and Methods of Use Thereof ABBOTT LABORATORIES (US) 2010-08-26 US disclosed
US-20100216762-A1 Agonists and Antagonists of the S1P5 Receptor, and Methods of Use Thereof ABBOTT LABORATORIES (US) 2010-08-26 US disclosed
EP-1335899-A2 SUBSTITUTED ALKYLDIAMINES AS INHIBITORS OF PLASMEPSIN OR RELATED PROTEASES Actelion Pharmaceuticals Ltd. (CH) 2003-08-20 EP disclosed
EP-1322612-A1 SUBSTITUTED AMINO-AZA-CYCLOALKANES USEFUL AGAINST MALARIA Actelion Pharmaceuticals Ltd. (CH) 2003-07-02 EP disclosed
WO-2002083641-A2 AMINO-AZA-CYCLOHEXANES FOR THE TREATMENT OF MALARIA ACTELION PHARMACEUTICALS LTD. (CH) 2002-10-24 WO disclosed
WO-2002038534-A2 SUBSTITUTED ALKYLDIAMINES AS INHIBITORS OF PLASMEPSIN OR RELATED PROTEASES ACTELION PHARMACEUTICALS LTD (CH) 2002-05-16 WO disclosed
WO-2002024649-A1 SUBSTITUTED AMINO-AZA-CYCLOALKANES USEFUL AGAINST MALARIA ACTELION PHARMACEUTICALS LTD (CH) 2002-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10626095-B2 Cyanotriazole compounds CS, PC, ACAT1 KIF11 3245/4885DRD1 4556/4885MAOB 3664/4885
US-20100216762-A1 Agonists and Antagonists of the S1P5 Receptor, and Methods of Use Thereof S1PR5, LPAR5, S1PR1 KIF11 3238/4885DRD1 821/4885MAOB 2578/4885
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS CS, PC, ACAT1 KIF11 3245/4885DRD1 4556/4885MAOB 3664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.